Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Phase 1/2 Completed 20 enrolled Clearside Biomedical, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.

Timeline

Start: 2016-11-10
Primary completion: 2017-10-17
Completion: 2017-10-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aflibercept	Protein / enzyme biologic	2 mg	Intravitreal
Subject	CLS-TA	Unknown	4 mg	Other

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

Summary

Timeline

Drugs

Indications